In Ontario, testing for predictive biomarkers including EGFR for lung adenocarcinoma, BRAF in malignant melanoma and KRAS and BRAF in metastatic colorectal cancer supports the use of targeted therapies for these patients. This evidence concerns the gene EGFR and metastatic colorectal cancer.